CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings

American Journal of Roentgenology

Volumn 183, Issue 6, 2004, Pages 1619-1628

  Choi, Haesun ^a   Charnsangavej, Chuslip ^a   Faria, Silvana De Castro ^a   Tamm, Eric P ^a   Benjamin, Robert S ^a   Johnson, Marcella M ^a   Macapinlac, Homer A ^a   Podoloff, Donald A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME; VISCERAL METASTASIS; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; RADIOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PIPERAZINES; PYRIMIDINES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 16644389881     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.183.6.01831619     Document Type: Article

References (21)

1. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214
2. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
3. Ollivier L. International criteria for tumour assessment. Cancer Imaging 2000;1:32-34
4. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003;9:713-725
5. Marsden P, Sutcliffe-Goulden J. Principles and technology of PET scanning. Nucl Med Commun 2000;21:221-224
6. Delbeke D. Oncological applications of FDG PET imaging. J Nucl Med 1999;40:1706-1715
7. Stokkel MP, Draisma A, Pauwels EK. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology: part IIIb-therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma. J Cancer Res Clin Oncol 2001;127:278-285
8. Strickland L, Letson GD, Muro-Cacho CA. Gastrointestinal stromal tumors. Cancer Control 2001;8:252-261
9. Rosai J. Gastrointestinal tract. In: Rosai J, Ewing J, eds. Ackerman's surgical pathology. St. Louis, MO:Mosby Year-Book, 1996:645-693
10. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000;15:1293-1301
11. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-795
12. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056
13. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenyIaminopyrimidine derivative. Cancer Res 1996;56:100-104
14. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7
15. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20:325-334
16. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations-European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur Cancer 1999;35:1773-1782
17. O'Doherty MJ. PET in oncology I: lung, breast, soft tissue sarcoma. Nucl Med Commun 2000;21:224-229
18. Devita VT Jr. Principles of cancer management: chemotherapy, 5th ed. Philadelphia, PA: Lippincott Raven, 1997:333-347
19. Schulte M, Brecht-Krauss D, Heymer B, et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur Nucl Med 1999;26:599-605
20. Van den Abbeele A, Badawi RD, Cliché J, et al. 18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). In: 2002 Annual meeting of the American Society of Clinical Oncology. Alexandria, VA: American Society of Clinical Oncology, 2002, Abstract 1610
21. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996;2:167-168